Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity”

Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity”

Bibliographic Details
Main Authors: Sidney A Schechet, Sarah Hilkert Rodriguez, Michael J Shapiro, Michael P Blair
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Taiwan Journal of Ophthalmology
Online Access:http://www.e-tjo.org/article.asp?issn=2211-5056;year=2019;volume=9;issue=2;spage=136;epage=137;aulast=Schechet
id doaj-9e947195dbd04bd4b9bccc6d9aec4edd
record_format Article
spelling doaj-9e947195dbd04bd4b9bccc6d9aec4edd2020-11-25T02:14:49ZengWolters Kluwer Medknow PublicationsTaiwan Journal of Ophthalmology2211-50562211-50722019-01-019213613710.4103/tjo.tjo_10_19Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity”Sidney A SchechetSarah Hilkert RodriguezMichael J ShapiroMichael P Blairhttp://www.e-tjo.org/article.asp?issn=2211-5056;year=2019;volume=9;issue=2;spage=136;epage=137;aulast=Schechet
collection DOAJ
language English
format Article
sources DOAJ
author Sidney A Schechet
Sarah Hilkert Rodriguez
Michael J Shapiro
Michael P Blair
spellingShingle Sidney A Schechet
Sarah Hilkert Rodriguez
Michael J Shapiro
Michael P Blair
Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity”
Taiwan Journal of Ophthalmology
author_facet Sidney A Schechet
Sarah Hilkert Rodriguez
Michael J Shapiro
Michael P Blair
author_sort Sidney A Schechet
title Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity”
title_short Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity”
title_full Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity”
title_fullStr Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity”
title_full_unstemmed Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity”
title_sort reply to comment on: “advantages of bevacizumab for aggressive posterior retinopathy of prematurity”
publisher Wolters Kluwer Medknow Publications
series Taiwan Journal of Ophthalmology
issn 2211-5056
2211-5072
publishDate 2019-01-01
url http://www.e-tjo.org/article.asp?issn=2211-5056;year=2019;volume=9;issue=2;spage=136;epage=137;aulast=Schechet
work_keys_str_mv AT sidneyaschechet replytocommentonadvantagesofbevacizumabforaggressiveposteriorretinopathyofprematurity
AT sarahhilkertrodriguez replytocommentonadvantagesofbevacizumabforaggressiveposteriorretinopathyofprematurity
AT michaeljshapiro replytocommentonadvantagesofbevacizumabforaggressiveposteriorretinopathyofprematurity
AT michaelpblair replytocommentonadvantagesofbevacizumabforaggressiveposteriorretinopathyofprematurity
_version_ 1724899497652256768

Similar Items